- Home
- RIG vs RYTM Comparison
RIG vs RYTM Comparison
Compare RIG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIG | RYTM |
|---|---|---|
| Founded | 1926 | 2008 |
| Country | Switzerland | United States |
| Employees | 5600 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.8B |
| IPO Year | 2008 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RIG | RYTM |
|---|---|---|
| Price | $5.92 | $110.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $7.10 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 45.8M | 667.9K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,973,000,000.00 | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | N/A | $86.06 |
| P/E Ratio | $28.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.93 | $74.50 |
| 52 Week High | $7.66 | $122.20 |
Technical Indicators
Market Signals| Indicator | RIG | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 49.96 |
| Support Level | $5.95 | $99.14 |
| Resistance Level | $7.03 | $112.43 |
| Average True Range (ATR) | 0.22 | 5.04 |
| MACD | 0.06 | -0.46 |
| Stochastic Oscillator | 82.72 | 57.22 |
Price Performance
Historical ComparisonAbout RIG Transocean Ltd (Switzerland)
Transocean Ltd. is an international provider of offshore contract drilling services for oil and gas wells. The company provides mobile offshore drilling rigs, related equipment, and crews to support the drilling of oil and gas wells. Its fleet mainly consists of offshore rigs, including drillships, semisubmersibles, and jackups.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.